Clinical Trials Logo

Thymidine Kinase 2 Deficiency clinical trials

View clinical trials related to Thymidine Kinase 2 Deficiency.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03845712 Active, not recruiting - Clinical trials for Thymidine Kinase 2 Deficiency

An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency

Continuation
Start date: July 5, 2019
Phase: Phase 2
Study type: Interventional

This is a Phase 2 prospective open-label treatment study of the safety and efficacy of doxecitine and doxribtimine in study participants with thymidine kinase 2 (TK2) deficiency who participated in the retrospective study MT-1621-101 [NCT03701568] or who were receiving nucleos(t)ide treatment and were approved by the Sponsor.

NCT ID: NCT03639701 Active, not recruiting - Clinical trials for Thymidine Kinase 2 Deficiency

Treatment of TK2 Deficiency With Thymidine and Deoxycytidine

Start date: May 16, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Patients with confirmed mitochondrial DNA depletion syndrome 2 (thymidine kinase 2 [TK2] deficiency) have reduced levels of nucleotides (deoxythymidine monophosphate and deoxycytidine monophosphate) for mitochondrial DNA synthesis. This results in mitochondrial DNA depletion syndrome (i.e less number of functional mitochondrial DNA). Patients with confirmed TK2 deficiency will be treated with open label deoxythymidine (dThd) and deoxycytidine (dCyt), which are nucleotide precursors, with the expectation that the cells could make additional mitochondrial DNA. This in turn may help reduce the clinical symptoms.